Corresponding authors: Bert Schepens, Xavier Saelens and Jason McLellan
Affiliations: Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA; VIB-UGent Center for Medical Biotechnology, VIB, 9052 Ghent, Belgium; Department of Biochemistry and Microbiology, Ghent University, 9052 Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA; Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research, 37077 Göttingen, Germany; Faculty of Biology and Psychology, University Göttingen, 37077 Göttingen, Germany.
Publication date: this article was published online on May 5, 2020
DOI: https://doi.org/10.1016/j.cell.2020.04.031
Highlights
Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. In this article, the authors describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. They also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion.
Nomination Reason
The data present in this article provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks.
----------------------------------------------------------------------------------------------------------------------------------------------
This article has been nominated for Distinguished Research Awards, you can visit the website below and vote for the nominated publications:
https://www.molecularcloud.org/awards-for-distinguished-research.html.
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud
Great piece of work.
单域抗体是治疗性抗体的热点,分子量更小,亲和力更强,靶向性更好,免疫原性更弱。目前已知羊驼、骆驼可以产生单域抗体。本文测试了骆驼产生的单域抗体的晶体结构,研究了抗体与SARS-CoV-2的结合机制,为开发治疗性抗体打下了基础